Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma
Saad AlShareef,1 Christine F McDonald,2– 4 Joy Lee2,5 1Department of Medicine, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 13317-4233, Saudi Arabia; 2Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Australia; 3Institute for Breathing and S...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-02-01
|
| Series: | Journal of Asthma and Allergy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/clinical-and-lung-function-outcomes-after-anti-ige-or-anti-il5-therapy-peer-reviewed-fulltext-article-JAA |
| _version_ | 1819278815967313920 |
|---|---|
| author | AlShareef S McDonald CF Lee J |
| author_facet | AlShareef S McDonald CF Lee J |
| author_sort | AlShareef S |
| collection | DOAJ |
| description | Saad AlShareef,1 Christine F McDonald,2– 4 Joy Lee2,5 1Department of Medicine, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 13317-4233, Saudi Arabia; 2Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Australia; 3Institute for Breathing and Sleep, Heidelberg, Australia; 4Faculty of Medicine, University of Melbourne, Melbourne, Australia; 5School of Public Health & Preventive Medicine, Monash University, Melbourne, AustraliaCorrespondence: Saad AlShareef, Email drsaad321@hotmail.comBackground: Although there have been indirect comparisons of the relative efficacy of mepolizumab (anti-IL-5) and benralizumab (anti-IL-5Rα) in severe asthma patients, long-term direct head-to-head comparisons are lacking. Here, we (i) examined the effect of mepolizumab, benralizumab, and omalizumab on symptom control and lung function parameters over time; and (ii) compared the efficacy of mepolizumab and benralizumab on symptom control and lung function outcomes.Methods: This was a retrospective study of patients with severe asthma taking anti-IgE (omalizumab; n = 24), anti-IL5 (mepolizumab, n = 23), or anti-IL-Rα (benralizumab; n = 12) therapy. Data were extracted on (i) Asthma Control Questionnaire (ACQ-5) scores; (ii) forced expiratory volume over 1 second (FEV1); and (iii) peak expiratory flow rate (PEFR) at 4– 6 months and 1 year and documented reductions in exacerbations. Clinical and lung function outcomes were compared between patients taking mepolizumab and benralizumab and over time.Results: There were significant decreases in ACQ-5 scores (3.3 ± 0.93 to 1.7 ± 0.98 for mepolizumab, 3.5 ± 0.72 to 1.6 ± 0.89 for benralizumab, and 3.5 ± 0.95 to 1.7 ± 1.1 for omalizumab; t-test, all p < 0.0001) but not increases in FEV1 and PEFR for all three agents after 4– 6 months of therapy, which persisted but did not decrease further at one year. There were trends toward a greater percentage increase in FEV1 and PEFR from baseline and a decrease in the number of exacerbations in patients taking benralizumab than those taking mepolizumab.Conclusion: Although limited by a small sample size, this real-world, head-to-head comparison of mepolizumab and benralizumab is consistent with comparative data on asthma biologicals and indirect comparisons showing no major difference in efficacy. The study also generates new testable hypotheses about the efficacy of asthma biologicals in different patient populations.Keywords: asthma, benralizumab, exacerbations, omalizumab, mepolizumab, monoclonal antibody |
| first_indexed | 2024-12-24T00:18:01Z |
| format | Article |
| id | doaj.art-64726e3ae50844ef908f2fc602a50a0d |
| institution | Directory Open Access Journal |
| issn | 1178-6965 |
| language | English |
| last_indexed | 2024-12-24T00:18:01Z |
| publishDate | 2022-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Asthma and Allergy |
| spelling | doaj.art-64726e3ae50844ef908f2fc602a50a0d2022-12-21T17:24:40ZengDove Medical PressJournal of Asthma and Allergy1178-69652022-02-01Volume 1520921772937Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe AsthmaAlShareef SMcDonald CFLee JSaad AlShareef,1 Christine F McDonald,2– 4 Joy Lee2,5 1Department of Medicine, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 13317-4233, Saudi Arabia; 2Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Australia; 3Institute for Breathing and Sleep, Heidelberg, Australia; 4Faculty of Medicine, University of Melbourne, Melbourne, Australia; 5School of Public Health & Preventive Medicine, Monash University, Melbourne, AustraliaCorrespondence: Saad AlShareef, Email drsaad321@hotmail.comBackground: Although there have been indirect comparisons of the relative efficacy of mepolizumab (anti-IL-5) and benralizumab (anti-IL-5Rα) in severe asthma patients, long-term direct head-to-head comparisons are lacking. Here, we (i) examined the effect of mepolizumab, benralizumab, and omalizumab on symptom control and lung function parameters over time; and (ii) compared the efficacy of mepolizumab and benralizumab on symptom control and lung function outcomes.Methods: This was a retrospective study of patients with severe asthma taking anti-IgE (omalizumab; n = 24), anti-IL5 (mepolizumab, n = 23), or anti-IL-Rα (benralizumab; n = 12) therapy. Data were extracted on (i) Asthma Control Questionnaire (ACQ-5) scores; (ii) forced expiratory volume over 1 second (FEV1); and (iii) peak expiratory flow rate (PEFR) at 4– 6 months and 1 year and documented reductions in exacerbations. Clinical and lung function outcomes were compared between patients taking mepolizumab and benralizumab and over time.Results: There were significant decreases in ACQ-5 scores (3.3 ± 0.93 to 1.7 ± 0.98 for mepolizumab, 3.5 ± 0.72 to 1.6 ± 0.89 for benralizumab, and 3.5 ± 0.95 to 1.7 ± 1.1 for omalizumab; t-test, all p < 0.0001) but not increases in FEV1 and PEFR for all three agents after 4– 6 months of therapy, which persisted but did not decrease further at one year. There were trends toward a greater percentage increase in FEV1 and PEFR from baseline and a decrease in the number of exacerbations in patients taking benralizumab than those taking mepolizumab.Conclusion: Although limited by a small sample size, this real-world, head-to-head comparison of mepolizumab and benralizumab is consistent with comparative data on asthma biologicals and indirect comparisons showing no major difference in efficacy. The study also generates new testable hypotheses about the efficacy of asthma biologicals in different patient populations.Keywords: asthma, benralizumab, exacerbations, omalizumab, mepolizumab, monoclonal antibodyhttps://www.dovepress.com/clinical-and-lung-function-outcomes-after-anti-ige-or-anti-il5-therapy-peer-reviewed-fulltext-article-JAAasthmabenralizumabexacerbationsomalizumabmepolizumabmonoclonal antibody |
| spellingShingle | AlShareef S McDonald CF Lee J Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma Journal of Asthma and Allergy asthma benralizumab exacerbations omalizumab mepolizumab monoclonal antibody |
| title | Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma |
| title_full | Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma |
| title_fullStr | Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma |
| title_full_unstemmed | Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma |
| title_short | Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma |
| title_sort | clinical and lung function outcomes after anti ige or anti il5 therapy in severe asthma |
| topic | asthma benralizumab exacerbations omalizumab mepolizumab monoclonal antibody |
| url | https://www.dovepress.com/clinical-and-lung-function-outcomes-after-anti-ige-or-anti-il5-therapy-peer-reviewed-fulltext-article-JAA |
| work_keys_str_mv | AT alshareefs clinicalandlungfunctionoutcomesafterantiigeorantiil5therapyinsevereasthma AT mcdonaldcf clinicalandlungfunctionoutcomesafterantiigeorantiil5therapyinsevereasthma AT leej clinicalandlungfunctionoutcomesafterantiigeorantiil5therapyinsevereasthma |